Literature DB >> 29941674

von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury.

Yingang Wu1,2,3, Wei Liu2,6, Yuan Zhou1,2, Tristan Hilton3, Zilong Zhao1,2, Wei Liu2,6, Min Wang4,5, Jason Yeon3, Katie Houck3, Perumal Thiagarajan7,8,9, Fangyi Zhang10, Fu-Dong Shi11,12, Xiaoping Wu4, Min Li5,6, Jing-Fei Dong4,12, Jianning Zhang1,2,3.   

Abstract

von Willebrand factor (VWF) is an adhesive ligand, and its activity is proteolytically regulated by the metalloprotease ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat 13). An elevated level of plasma VWF has been widely considered a marker for endothelial cell activation in trauma and inflammation, but its causal role in these pathological conditions remains poorly defined. Using a fluid percussion injury mouse model, we demonstrated that VWF released during acute traumatic brain injury (TBI) was activated and became microvesicle-bound. The VWF-bound microvesicles promoted vascular leakage and systemic coagulation. Recombinant ADAMTS-13 given either before or after TBI reduced the VWF reactivity with minimal influence on VWF secretion. rADAMTS-13 protected the integrity of endothelial cell barriers and prevented TBI-induced coagulopathy by enhancing VWF cleavage without impairing basal hemostasis. Promoting microvesicle clearance by lactadherin had efficacy similar to that of rADAMTS-13. This study uncovers a novel synergistic action between VWF and cellular microvesicles in TBI-induced vascular leakage and coagulopathy and demonstrates protective effects of rADAMTS-13.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29941674      PMCID: PMC6128082          DOI: 10.1182/blood-2018-03-841932

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  34 in total

1.  Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.

Authors:  Koji Habe; Hideo Wada; Naomi Ito-Habe; Tsuyoshi Hatada; Takeshi Matsumoto; Kohshi Ohishi; Kazuo Maruyama; Hiroshi Imai; Hitoshi Mizutani; Tsutomu Nobori
Journal:  Thromb Res       Date:  2011-11-08       Impact factor: 3.944

2.  ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.

Authors:  H B Feys; F Liu; N Dong; I Pareyn; S Vauterin; N Vandeputte; W Noppe; C Ruan; H Deckmyn; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2006-05       Impact factor: 5.824

3.  Cardiolipin-mediated procoagulant activity of mitochondria contributes to traumatic brain injury-associated coagulopathy in mice.

Authors:  Zilong Zhao; Min Wang; Ye Tian; Tristan Hilton; Breia Salsbery; Eric Z Zhou; Xiaoping Wu; Perumal Thiagarajan; Eric Boilard; Min Li; Jianning Zhang; Jing-Fei Dong
Journal:  Blood       Date:  2016-03-21       Impact factor: 22.113

4.  Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice.

Authors:  Georgette L Suidan; Alexander Brill; Simon F De Meyer; Jaymie R Voorhees; Stephen M Cifuni; Jessica E Cabral; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-03       Impact factor: 8.311

5.  von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support.

Authors:  Angelo Nascimbene; Tristan Hilton; Barbara A Konkle; Joel L Moake; O H Frazier; Jing-Fei Dong
Journal:  J Heart Lung Transplant       Date:  2017-01-13       Impact factor: 10.247

6.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-κB signaling pathway in experimental traumatic brain injury.

Authors:  Weiwei Gao; Zilong Zhao; Gongjie Yu; Ziwei Zhou; Yuan Zhou; Tingting Hu; Rongcai Jiang; Jianning Zhang
Journal:  Brain Res       Date:  2015-06-12       Impact factor: 3.252

Review 8.  Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura.

Authors:  J L Moake; T W Chow
Journal:  J Clin Apher       Date:  1998       Impact factor: 2.821

Review 9.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.

Authors:  Frederik Denorme; Peter Kraft; Inge Pareyn; Christiane Drechsler; Hans Deckmyn; Karen Vanhoorelbeke; Christoph Kleinschnitz; Simon F De Meyer
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

View more
  25 in total

1.  Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.

Authors:  Derek J B Kleinveld; Derek D G Simons; Charlotte Dekimpe; Shannen J Deconinck; Pieter H Sloos; M Adrie W Maas; Jesper Kers; Joshua Muia; Karim Brohi; Jan Voorberg; Karen Vanhoorelbeke; Markus W Hollmann; Nicole P Juffermans
Journal:  Blood Adv       Date:  2021-09-14

2.  Prognostic Significance of Plasma Insulin Level for Deep Venous Thrombosis in Patients with Severe Traumatic Brain Injury in Critical Care.

Authors:  Min Du; Qing-Hong Zhang; Rui Tang; Hai-Yan Liu; Zong-Shu Ji; Zhi Gao; Ying Wang; He-Yang You; Ji-Wei Hao; Min Zhou
Journal:  Neurocrit Care       Date:  2022-09-16       Impact factor: 3.532

3.  Anticoagulation targeting membrane-bound anionic phospholipids improves outcomes of traumatic brain injury in mice.

Authors:  Xinlong Dong; Wei Liu; Yu Shen; Katie Houck; Mengchen Yang; Yuan Zhou; Zilong Zhao; Xiaoping Wu; Teri Blevins; Amanda L Koehne; Tze-Chein Wun; Xiaoyun Fu; Min Li; Jianning Zhang; Jing-Fei Dong
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 4.  Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy.

Authors:  Xin Xu; Rosemary Kozar; Jianning Zhang; Jing-Fei Dong
Journal:  J Thromb Haemost       Date:  2020-10-06       Impact factor: 5.824

Review 5.  Links between thrombosis and inflammation in traumatic brain injury.

Authors:  W Brad Hubbard; Jing-Fei Dong; Miguel A Cruz; Rolando E Rumbaut
Journal:  Thromb Res       Date:  2020-11-25       Impact factor: 3.944

6.  Death after discharge: prognostic model of 1-year mortality in traumatic brain injury patients undergoing decompressive craniectomy.

Authors:  Wenxing Cui; Shunnan Ge; Yingwu Shi; Xun Wu; Jianing Luo; Haixiao Lui; Gang Zhu; Hao Guo; Dayun Feng; Yan Qu
Journal:  Chin Neurosurg J       Date:  2021-04-21

7.  Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness.

Authors:  William E Plautz; Zachary A Matthay; Marian A Rollins-Raval; Jay S Raval; Lucy Z Kornblith; Matthew D Neal
Journal:  Transfusion       Date:  2020-06-01       Impact factor: 3.157

Review 8.  Extracellular Vesicles as an Emerging Frontier in Spinal Cord Injury Pathobiology and Therapy.

Authors:  Dipankar Dutta; Niaz Khan; Junfang Wu; Steven M Jay
Journal:  Trends Neurosci       Date:  2021-02-11       Impact factor: 16.978

9.  Conformation-dependent blockage of activated VWF improves outcomes of traumatic brain injury in mice.

Authors:  Xin Xu; Chenyu Wang; Yingang Wu; Katie Houck; Tristan Hilton; Ashley Zhou; Xiaoping Wu; Cha Han; Mengchen Yang; Wei Yang; Fu-Dong Shi; Moritz Stolla; Miguel A Cruz; Min Li; Jianning Zhang; Jing-Fei Dong
Journal:  Blood       Date:  2021-01-28       Impact factor: 25.476

10.  Risk Factors for Cerebral Infarction After Moderate or Severe Traumatic Brain Injury.

Authors:  Yin-Gang Wu; Yingjiu Chao; Ge Gao; Dejun Bao; Yongfei Dong; Xiangpin Wei; Chaoshi Niu
Journal:  Ther Clin Risk Manag       Date:  2021-05-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.